Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy drug shows promise in preventing High-Risk skin cancer recurrence

NCT ID NCT03833167

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent skin cancer from returning in people with high-risk locally advanced squamous cell carcinoma who had already undergone surgery and radiation. About 450 participants were randomly assigned to receive either pembrolizumab or a placebo. The main goal was to see if the drug could extend the time before the cancer came back or spread. While not a cure, this approach aims to better control the disease and improve outcomes for patients at high risk of recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

450 people

The number who actually took part.

Started

Apr 2019

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion Criteria include, but are not limited to: * Has histologically confirmed cutaneous squamous cell carcinoma (cSCC) as the primary site of malignancy (metastatic skin involvement from another type of primary cancer or from an unknown primary cancer is not permitted) * Has histologically confirmed locally advanced cutaneous squamous cell carcinoma (LA cSCC) with ≥1 high-risk feature(s) as the primary site of malignancy * Has undergone complete macroscopic resection of all known cSCC disease with or without microscopic positive margins. For those participants with residual microscopic positive margin involvement, confirmation that additional re-excision is not possible must be provided * Has completed adjuvant radiotherapy (RT) for LA cSCC with last dose of RT ≥4 weeks and ≤16 weeks from randomization * Has received an adequate post-op dose of RT (either hypofractionated or conventional) * Is disease free as assessed by the investigator with complete radiographic staging assessment ≤28 days from randomization * Is not pregnant or breastfeeding * Is not a person of childbearing potential (POCBP) * Has a negative pregnancy test ≤72 hours before the first dose of study intervention. * Has provided an archival or newly-obtained tumor tissue sample adequate for Programmed Cell Death Ligand 1 (PD-L1) testing as determined by central laboratory testing * Has a life expectancy of \>3 months * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ≤10 days prior to the first dose of study intervention. Exclusion Criteria: Exclusion criteria include, but are not limited to: * Has macroscopic residual cSCC after surgery and/or recurrence with active cSCC disease before randomization * Has any other histologic type of skin cancer other than invasive cSCC (eg, basal cell carcinoma) that has not been definitively treated with surgery or radiation; Bowen's disease; Merkel cell carcinoma; or melanoma * Has received prior therapy with an anti-programmed cell death receptor 1(PD-1), anti-PD-L1, or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another costimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\], OX-40, CD137) * Has received prior systemic anticancer therapy including investigational agents for cSCC ≤4 weeks prior to before start of study intervention. * Has not recovered from all radiation-related toxicities and has not had radiation pneumonitis * Has received a live vaccine ≤30 days prior to the first dose of study intervention * Has received an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. * Has known additional malignancy that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded. Other exceptions may be considered with Sponsor consultation. Note: Participants with low risk early-stage prostate cancer defined as below are not excluded: Stage T1c or T2a with a Gleason score ≤6 and a prostate-specific antigen (≤10 ng/ml) either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study allocation. Early stage asymptomatic CLL without prior treatment and without any of the risk features (unmutated IGHV, lymphocytes \>15,000μL, palpable lymph nodes) will be eligible for the study * Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid). * Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Has an active infection requiring systemic therapy * Has a known history of human immunodeficiency virus (HIV) infection * Has a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (HCV; defined as HCV RNA \[qualitative\] is detected) infection * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention * Has had an allogeneic tissue/solid organ transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, squamous cell are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

skin squamous cell carcinoma squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, squamous cell

Contacts and locations

Locations

  • A. C. Camargo Cancer Center ( Site 0116)

    São Paulo, 01509-010, Brazil

  • A. Tsyb Medical Radiological Research Center - branch of the National Medical Research Radiological

    Obninsk, Kaluzskaja Oblast, 249036, Russia

  • Alfred Health ( Site 0055)

    Melbourne, Victoria, 3004, Australia

  • Altay Regional Oncology Dispensary ( Site 1168)

    WBarnaularsaw, Altayskiy Kray, 656045, Russia

  • Andreas Syggros Hospital ( Site 0450)

    Athens, Achaia, 161 21, Greece

  • Attikon University General Hospital of Athens ( Site 0454)

    Chaïdári, Attica, 124 62, Greece

  • Azienda Ospedaliero Universitaria Pisana ( Site 0603)

    Pisa, Tuscany, 56126, Italy

  • Boca Raton Regional Hospital ( Site 1551)

    Boca Raton, Florida, 33486, United States

  • Bradford Hill Norte ( Site 1652)

    Antofagasta, 1240000, Chile

  • Bradfordhill ( Site 1651)

    Santiago, Region M. de Santiago, 8420383, Chile

  • C.H.U. de Nimes. Hopital Caremeau ( Site 0368)

    Nîmes, Gard, 30029, France

  • CEMIC ( Site 0012)

    Buenos Aires, C1431FWO, Argentina

  • CH Lyon Sud Hospices Civils de Lyon ( Site 0350)

    Pierre-Bénite, Rhone, 69495, France

  • CHLN Hospital Santa Maria ( Site 1001)

    Lisbon, 1649-035, Portugal

  • CHRU de Lille - Hopital Claude Huriez ( Site 0355)

    Lille, Nord, 59037, France

  • CHU Besancon - Hopital Jean Minjoz ( Site 0359)

    Besançon, Doubs, 25030, France

  • CHU Estaing ( Site 0360)

    Clermont-Ferrand, Puy-de-Dome, 63003, France

  • CHU Montpellier. ( Site 0367)

    Montpellier, Herault, 34295, France

  • CHU Poitiers ( Site 0375)

    Poitiers, Vienne, 86021, France

  • CHU de Bordeaux- Hopital Saint Andre ( Site 0370)

    Bordeaux, Gironde, 33075, France

  • CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0163)

    Montreal, Quebec, H1T 2M4, Canada

  • Cardiomed SRL Cluj-Napoca ( Site 1104)

    Cluj-Napoca, Cluj, 400015, Romania

  • Centre Hospitalier Annecy Genevois ( Site 0361)

    Pringy, Haute-Savoie, 74374, France

  • Centre Hospitalier Universitaire de Caen Normandie-DERMATOLOGY ( Site 0365)

    Caen, Calvados, 14000, France

  • Centre Hospitalier de Valence ( Site 0377)

    Valence, Drome, 26953, France

  • Centro Estatal de Cancerologia de Chihuahua ( Site 0703)

    Chihuahua City, 31000, Mexico

  • Centro Medico Privado CEMAIC ( Site 0024)

    Capital, Córdoba Province, X5008HHW, Argentina

  • Centro Oncologico Norte ( Site 0023)

    Santiago del Estero, G4200AWD, Argentina

  • Centro Oncologico Riojano Integral ( Site 0002)

    La Rioja, F5300COE, Argentina

  • Centro Oncológico de Rosario ( Site 0003)

    Rosario, Santa Fe Province, S2000KZE, Argentina

  • Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0028)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1027AAP, Argentina

  • Centro de Investigación Clínica de Alta Especialidad ( Site 0715)

    Torreón, Coahuila, 27010, Mexico

  • Centro de atencion e investigacion clinica en oncologia ( Site 0706)

    Mérida, Yucatán, 97134, Mexico

  • Chaim Sheba Medical Center ( Site 0551)

    Ramat Gan, 5265601, Israel

  • Chris OBrien Lifehouse ( Site 0051)

    Camperdown, New South Wales, 2050, Australia

  • Churchill Hospital ( Site 1404)

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

  • Cimab SA de CV ( Site 0708)

    Torreón, Coahuila, 27000, Mexico

  • City of Hope Medical Center ( Site 1505)

    Duarte, California, 91010, United States

  • Cleveland Clinic ( Site 1541)

    Cleveland, Ohio, 44195, United States

  • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Department for daily treated patient (

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine

  • Consultorios de Medicina Especializada del Sector Privado ( Site 0701)

    Guadalajara, Jalisco, 44680, Mexico

  • Cross Cancer Institute ( Site 0159)

    Edmonton, Alberta, T6G 1Z2, Canada

  • Dana Farber Cancer Center ( Site 1519)

    Boston, Massachusetts, 02215, United States

  • Debreceni Egyetem. ( Site 0506)

    Debrecen, Vas County, 4032, Hungary

  • Elbe Kliniken Stade-Buxtehude, Klinikum Buxtehude-Dermatologisches Zentrum ( Site 0411)

    Buxtehude, Lower Saxony, 21614, Germany

  • Enroll SpA ( Site 1654)

    Santiago, Region M. de Santiago, 7500587, Chile

  • European Interbalkan Medical Center ( Site 0455)

    Thessaloniki, 570 01, Greece

  • FAICIC Clinical Research ( Site 0700)

    Veracruz, 91900, Mexico

  • FSCC FMBA of Russia ( Site 1163)

    Moscow, Moscow, 115682, Russia

  • First Moscow State Medical University n.a. I.M.Sechenov ( Site 1164)

    Moscow, Moscow, 119991, Russia

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0600)

    Milan, 20133, Italy

  • Fundacion CIDEA ( Site 0001)

    CABA, C1121ABE, Argentina

  • Fundacion Estudios Clinicos-Oncology ( Site 0026)

    Rosario, Santa Fe Province, S2000DEJ, Argentina

  • Fundación Cardiovascular de Colombia ( Site 0207)

    Piedecuesta, Santander Department, 68017, Colombia

  • Fundación Valle del Lili ( Site 0202)

    Cali, Valle del Cauca Department, 760032, Colombia

  • GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 1171)

    Ufa, Baskortostan, Respublika, 450054, Russia

  • Gold Coast University Hospital ( Site 0054)

    Southport, Queensland, 4215, Australia

  • Guy s & St Thomas NHS Foundation Trust ( Site 1407)

    London, London, City of, SE1 9RT, United Kingdom

  • Hadassah Medical-Oncology department ( Site 1173)

    Moscow, Moscow Oblast, 121205, Russia

  • Haddassah Medical Organization - Ein Kerem ( Site 0553)

    Jerusalem, 9112001, Israel

  • Haukeland sykehus ( Site 0851)

    Bergen, Hordaland, 5021, Norway

  • Hifu Terramed Conformal SRL ( Site 1111)

    Bucharest, Bucharest, 031864, Romania

  • Hopital ARCHET 2 ( Site 0356)

    Nice, Alpes-Maritimes, 06200, France

  • Hopital Avicenne ( Site 0358)

    Bobigny, Seine-Saint-Denis, 93009, France

  • Hopital La Timone ( Site 0353)

    Marseille, Bouches-du-Rhone, 13385, France

  • Hopital Saint Joseph ( Site 0376)

    Marseille, Bouches-du-Rhone, 13285, France

  • Hospital Bruno Born ( Site 0107)

    Lajeado, Rio Grande do Sul, 95900-000, Brazil

  • Hospital CUF - Tejo ( Site 1004)

    Lisbon, 1350-352, Portugal

  • Hospital Clinic i Provincial Barcelona ( Site 1253)

    Barcelona, Catalonia, 08036, Spain

  • Hospital Duran i Reynals ( Site 1254)

    Hospitalet Del Llobregat, Barcelona, 08908, Spain

  • Hospital Erasto Gaertner ( Site 0101)

    Curitiba, Paraná, 81520-060, Brazil

  • Hospital General Universitari Vall d Hebron ( Site 1252)

    Barcelona, 08035, Spain

  • Hospital Italiano- Sociedad Italiana de Beneficencia en Buenos Aires ( Site 0009)

    Buenos Aires, C1181ACH, Argentina

  • Hospital Particular do Algarve ( Site 1005)

    Faro, 8005-226, Portugal

  • Hospital Sao Vicente de Paulo ( Site 0105)

    Passo Fundo, Rio Grande do Sul, 99010-080, Brazil

  • Hospital Tacchini ( Site 0111)

    Bento Gonçalves, Rio Grande do Sul, 95700-084, Brazil

  • Hospital Universitario Carlos Haya ( Site 1255)

    Málaga, 29010, Spain

  • Hospital Universitario Marques de Valdecilla ( Site 1256)

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Ramon y Cajal ( Site 1251)

    Madrid, 28034, Spain

  • Hospital de Especialidades Centro Medico de Occidente ( Site 0704)

    Guadalajara, Jalisco, 44349, Mexico

  • Huntsman Cancer Institute ( Site 1537)

    Salt Lake City, Utah, 84112, United States

  • Icahn School of Medicine at Mount Sinai ( Site 1575)

    New York, New York, 10029, United States

  • Indiana University Melvin and Bren Simon Cancer Center ( Site 1515)

    Indianapolis, Indiana, 46202, United States

  • Inova Schar Cancer Institute ( Site 1538)

    Fairfax, Virginia, 22031, United States

  • Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 1000)

    Porto, 4200-072, Portugal

  • Institut Claudius Regaud IUCT Oncopole ( Site 0354)

    Toulouse, Haute-Garonne, 31059, France

  • Institut Gustave Roussy ( Site 0352)

    Villejuif, Val-de-Marne, 94800, France

  • Institute of General and Emergency Surgery named after V.T. Zaitsev NAMS of Ukraine ( Site 1450)

    Kharkiv, Kharkiv Oblast, 61103, Ukraine

  • Instituto Nacional de Cancerologia E.S.E ( Site 0204)

    Bogotá, Bogota D.C., 111511, Colombia

  • Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA-Pesquisa Clinica HC II ( Site 0103)

    Rio de Janeiro, 20220-410, Brazil

  • Instituto Portugues de Oncologia de Lisboa ( Site 1003)

    Lisbon, 1099-023, Portugal

  • Instituto Tumori Giovanni Paolo II ( Site 0604)

    Bari, Apulia, 70124, Italy

  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1113)

    Cluj-Napoca, Cluj, 400015, Romania

  • Istituto Europeo di Oncologia ( Site 0602)

    Milan, 20141, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0601)

    Naples, 80131, Italy

  • James Lind Centro de Investigación del Cáncer ( Site 1653)

    Temuco, Araucania, 4800827, Chile

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1526)

    Hackensack, New Jersey, 07601, United States

  • Juravinski Cancer Center ( Site 0151)

    Hamilton, Ontario, L8V 1C3, Canada

  • Klinikum Nürnberg Nord ( Site 0415)

    Nuremberg, Bavaria, 90419, Germany

  • Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 1451)

    Kropyvnytskyi, Kirovohrad Oblast, 25011, Ukraine

  • Lismore Base Hospital ( Site 0050)

    Lismore, New South Wales, 2480, Australia

  • MUSC Hollings Cancer Center ( Site 1533)

    Charleston, South Carolina, 29425, United States

  • Massachusetts General Hospital ( Site 1518)

    Boston, Massachusetts, 02114, United States

  • McGill University Health Centre ( Site 0162)

    Montreal, Quebec, H4A 3J1, Canada

  • Medizinische Hochschule Hannover ( Site 0405)

    Hanover, Lower Saxony, 30625, Germany

  • Meir Medical Center ( Site 0556)

    Kfar Saba, 4428132, Israel

  • Metropolitan Hospital ( Site 0453)

    Neo Faliro, Attica, 185 47, Greece

  • N.N. Blokhin NMRCO ( Site 1153)

    Moscow, Moscow, 115478, Russia

  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0958)

    Gliwice, Silesian Voivodeship, 44-101, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0951)

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 0959)

    Krakow, Lesser Poland Voivodeship, 31-115, Poland

  • New Zealand Clinical Research (Auckland) ( Site 0800)

    Auckland, 0624, New Zealand

  • Nizhniy Novgorod regional clinical oncological dispensary ( Site 1169)

    Nizhny Novgorod, Nizhny Novgorod Oblast, 603126, Russia

  • Northwell Health/ RJ Zuckerberg Cancer Center-Medical Oncology ( Site 1565)

    Lake Success, New York, 11042, United States

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0100)

    Ijuí, Rio Grande do Sul, 98700000, Brazil

  • Onco-Hematologia de Occidente ( Site 0716)

    Guadalajara, Jalisco, 44260, Mexico

  • Oncocentro Ceara ( Site 0108)

    Fortaleza, Ceará, 60135-237, Brazil

  • Oncological Dispensary #2 of Ministry of Health of Krasnodar region ( Site 1159)

    Sochi, Krasnodarskiy Kray, 354057, Russia

  • Oncologos del Occidente S.A. ( Site 0206)

    Pereira, Risaralda Department, 660001, Colombia

  • Oncomedica S.A. ( Site 0205)

    Montería, Departamento de Córdoba, 230002, Colombia

  • Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1258)

    Doniostia - San Sebastian, Gipuzkoa, 20014, Spain

  • Orange Health Services ( Site 0053)

    Orange, New South Wales, 2800, Australia

  • Oslo Universitetssykehus Radiumhospitalet ( Site 0850)

    Oslo, 0379, Norway

  • Papageorgiou General Hospital ( Site 0451)

    Thessaloniki, 564 03, Greece

  • Pecsi Tudomanyegyetem AOK ( Site 0501)

    Pécs, Baranya, 7632, Hungary

  • Policlinica Oncomed SRL ( Site 1105)

    Timișoara, Timiș County, 300239, Romania

  • Providence Portland Medical Center ( Site 1530)

    Portland, Oregon, 97213, United States

  • Rabin Medical Center ( Site 0550)

    Petah Tikva, 4941492, Israel

  • Railway Hospital of OJSC ( Site 1161)

    Saint Petersburg, Sankt-Peterburg, 195271, Russia

  • Rambam Health Care Campus-Oncology Division ( Site 0552)

    Haifa, 3109601, Israel

  • Royal Cornwall Hospitals NHS Trust ( Site 1402)

    Truro, Cornwall, TR1 3LQ, United Kingdom

  • Royal Marsden NHS Foundation Trust ( Site 1408)

    Sutton, London, City of, SM2 5PT, United Kingdom

  • Royal North Shore Hospital ( Site 0052)

    St Leonards, New South Wales, 2065, Australia

  • S C Oncocenter Oncologie Medicala S R L ( Site 1106)

    Timișoara, Timiș County, 300166, Romania

  • S C Pelican Impex SRL ( Site 1108)

    Oradea, Bihor County, 410469, Romania

  • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1101)

    Craiova, Dolj, 200347, Romania

  • S.C.Focus Lab Plus S.R.L ( Site 1107)

    Bucharest, 022548, Romania

  • San Lucas Cardiologica del Sureste S.A de C.V. ( Site 0722)

    Tuxtla Gutiérrez, Chiapas, 29090, Mexico

  • Semmelweis Egyetem ( Site 0507)

    Budapest, 1083, Hungary

  • Smilow Cancer Center at Yale-New Haven ( Site 1507)

    New Haven, Connecticut, 06510, United States

  • Sociedad de Cirugía de Bogotá - Hospital de San Jose ( Site 0201)

    Bogotá, Bogota D.C., 111411, Colombia

  • Soroka University Medical Center ( Site 0555)

    Beersheba, 8410101, Israel

  • Sourasky Medical Center ( Site 0554)

    Tel Aviv, 6423906, Israel

  • Spitalul Universitar CF Cluj-Napoca ( Site 1103)

    Cluj-Napoca, Cluj, 400015, Romania

  • Spitalul de Psihiatrie Titan Dr. Constantin Gorgos ( Site 1112)

    Bucharest, 030447, Romania

  • St. James s Hospital ( Site 1601)

    Dublin, Dublin, D08 K0Y5, Ireland

  • St. Olavs Hospital HF ( Site 0852)

    Trondheim, Sor-Trondelag, 7030, Norway

  • Stanford University Medical Center ( Site 1503)

    Stanford, California, 94305, United States

  • Sumy regional clinical oncological dispensary-Oncothoracic department ( Site 1452)

    Sumy, Sumska Oblast, 40022, Ukraine

  • Sunshine Coast University Private Hospital-Coastal Cancer Care ( Site 0056)

    Sunshine Coast, Queensland, 4575, Australia

  • Szabolcs Szatmar Bereg Megyei Korhazak es Egyetemi Oktatokorhaz ( Site 0500)

    Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400, Hungary

  • Szegedi Tudomanyegyetem ( Site 0504)

    Szeged, Csongrád megye, 6720, Hungary

  • Szent Imre Egyetemi Oktatokorhaz ( Site 0502)

    Budapest, 1115, Hungary

  • The Ottawa Hospital Cancer Centre ( Site 0154)

    Ottawa, Ontario, K1H 8L6, Canada

  • The Royal Marsden Hospital-Institute of Cancer Research ( Site 1406)

    London, London, City of, SW3 6JJ, United Kingdom

  • The University of Texas-MD Anderson Cancer Center ( Site 1536)

    Houston, Texas, 77030, United States

  • Tom Baker Cancer Center ( Site 0161)

    Calgary, Alberta, T2N 4N2, Canada

  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1568)

    Los Angeles, California, 90095, United States

  • UCSD Moores Cancer Center ( Site 1561)

    La Jolla, California, 92093-0698, United States

  • UF Health ( Site 1511)

    Gainesville, Florida, 32608, United States

  • UPMC Hillman Cancer Center ( Site 1570)

    Pittsburgh, Pennsylvania, 15232, United States

  • Udmurtia Republic Regional Clinical Oncology Dispensary ( Site 1158)

    Izhevsk, Udmurtiya Republic, 426009, Russia

  • Universal Clinic Oberig-Oncology Center ( Site 1461)

    Kyiv, 03057, Ukraine

  • Universitaetsklinikum Berlin - Charite - Campus Mitte ( Site 0400)

    Berlin, 10117, Germany

  • Universitaetsklinikum Essen ( Site 0403)

    Essen, North Rhine-Westphalia, 45147, Germany

  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0414)

    Hamburg, 20246, Germany

  • Universitaetsklinikum Tuebingen ( Site 0409)

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Universitatsklinikum Giessen und Marburg GmbH ( Site 0413)

    Marburg, Hesse, 35043, Germany

  • University College Hospital London ( Site 1400)

    London, London, City of, NW1 2PG, United Kingdom

  • University of California Davis Comprehensive Cancer Center ( Site 1560)

    Sacramento, California, 95817, United States

  • University of Colorado Cancer Center ( Site 1506)

    Aurora, Colorado, 80045, United States

  • University of Iowa Hospital and Clinics ( Site 1514)

    Iowa City, Iowa, 52242, United States

  • University of Kentucky School of Medicine & Hospitals ( Site 1542)

    Lexington, Kentucky, 40536, United States

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1544)

    Miami, Florida, 33136, United States

  • University of South Alabama, Mitchell Cancer Institute ( Site 1562)

    Mobile, Alabama, 36604, United States

  • Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Vanderbilt Ingram Cancer Center ( Site 1543)

    Nashville, Tennessee, 37232, United States

  • West Cancer Center - East Campus ( Site 1535)

    Germantown, Tennessee, 38138, United States

  • West Virginia University ( Site 1569)

    Morgantown, West Virginia, 26506, United States

  • Winship Cancer Institute of Emory University ( Site 1512)

    Atlanta, Georgia, 30322-1013, United States

  • Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1152)

    Yaroslavl, Yaroslavl Oblast, 150054, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.